Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) 2025 Annual Report: Key Investor Insights

Overview and Strategic Positioning

2025 was a pivotal year for Jiuyuan Gene, marking its first full financial year since listing and coinciding with its 30th anniversary. The company navigated macroeconomic pressures, significant restructuring within the pharmaceutical sector, and evolving policy environments with a focus on innovation, operational efficiency, and long-term value creation. The management’s commitment to “long-termism” and structural optimization has positioned Jiuyuan Gene for its next phase of growth.

Industry Landscape and Market Trends

• China’s pharmaceutical industry saw a surge in high-quality development driven by innovation and policy support.
• The number of innovative drugs approved by China’s NMPA reached historic highs.
• AI adoption accelerated R&D efficiency, reducing early-stage costs.
• Government support focused on products addressing unmet clinical needs and those with significant advantages.
• Investment confidence in innovative drug sectors remained strong, with A-share and H-share markets outperforming.

Financial Performance and Dividend Announcement

• Revenue & Profit: Consolidated net profit attributable to shareholders for 2025 was approximately RMB138.4 million.
• Dividend: The Board proposed a final cash dividend of RMB0.57 (inclusive of tax) per 10 shares, totalling RMB13.77 million. This represents ~9.95% of net profit and awaits AGM approval, with payment targeted for July 30, 2026.
• Distributable reserves: RMB246.5 million as of December 31, 2025.
• Gearing Ratio: 22%, indicating prudent capital management.

Shareholder Actions and Corporate Events

• Share Repurchase: Between January 13 and February 12, 2026, Jiuyuan Gene repurchased 3,882,400 H Shares as treasury shares for HK\$40.21 million. This aims to increase net asset value per share and earnings per share.
• Public Float: As of the report date, public float fell to ~22.22% due to the repurchase, below the 25% minimum required under HKEX rules. The company is executing a restoration plan via H Share Full Circulation, converting 136,302,015 Unlisted Shares into H Shares. Upon completion, the public float is expected to rise to ~31.13%, restoring compliance with HKEX requirements.
• 2026 Share Award Scheme: The Board resolved to propose a new share award scheme to attract and retain talent as part of its long-term incentive strategy. Approval will be sought at an extraordinary general meeting.

Corporate Governance and Compliance

• Comprehensive risk management and internal control systems are in place, regularly reviewed by both internal and external consultants.
• The company complied with all relevant laws and HKEX requirements, with no material litigation, penalties, or regulatory investigations during the reporting period.
• Director and management training on compliance, governance, and ESG was conducted throughout the year.

Connected Transactions and Related Party Disclosures

• Continuing connected transactions with Huadong Medicine and others were found to be conducted on normal commercial terms and within annual caps, with unqualified auditor assurance.
• No material interests in competing businesses among directors or their associates.

Material Investments, Acquisitions, and Disposals

• No significant investments, material acquisitions, or disposals occurred during 2025.
• No convertible bonds or debentures were issued, and no material contingent liabilities were reported.

Risks and Uncertainties

• Regulatory changes, pricing reforms, and volume-based procurement may affect revenues and margins.
• Success in tender processes with public hospitals is critical for market share and profitability.
• Maintaining an effective distribution network is vital; disruptions could impact performance.

Employee Incentives and Shareholding Platforms

• Three employee shareholding platforms (Chengheda, Nanbeiju, Qingfanghao) incentivize staff, with current schemes not diluting existing shareholders.
• Competitive remuneration and extensive training programs are in place to attract and retain talent.

Shareholder Communication

• Jiuyuan Gene has robust policies for shareholder communication, privacy, and investor relations, including regular updates, meetings, and accessible information via its website and HKEX.
• Shareholders can propose resolutions and communicate directly with the Board and company secretary.

Potential Price-Sensitive Highlights

• Share Repurchase and Public Float Restoration: The recent buyback and planned conversion of Unlisted Shares into H Shares are expected to boost earnings per share and restore public float above the regulatory minimum, potentially enhancing investor confidence and share value.
• Dividend Proposal: The cash dividend, if approved, may be viewed positively by investors seeking returns.
• Share Award Scheme: A new share incentive plan could improve talent retention and company performance.
• Strong Governance and Compliance: No material legal or regulatory issues, supporting stability and investor trust.
• Industry Trends: Continued focus on high-quality, innovative drug development aligns Jiuyuan Gene with sector growth drivers.

Conclusion

Jiuyuan Gene’s 2025 Annual Report signals a robust financial and operational position, proactive governance, and a strategic focus on innovation and shareholder value. The upcoming dividend, share repurchase, and restoration of public float are crucial developments for investors. The absence of material litigation, strong compliance, and ongoing talent incentives further reinforce its growth prospects in a dynamic pharmaceutical market.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult financial advisors before making decisions related to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. The information is based on the company’s published annual report and may be subject to change.

View JIUYUAN GENE Historical chart here